

## Biosceptre Cancer Drug Treatment Jan 2020 update

Biosceptre Company is intending to raise up to £20 million for a 7.6% equity position, and to identify suitable domestic distribution partners to support their entry into the Chinese market.

The company is looking to raise this new capital on a pre-money valuation of £200 million. To date the company has commitments for approx. 50% of the raise, including Tus park which contributed a further £1 million pounds (18 months ago they invested £5 million pounds) to maintain their 5% shareholding. All funds have been raised at £5.22 per share.

Biosceptre is a UK-based clinical stage immune –oncology company that has identified a novel and valuable cancer target marker (nfP2X7) that only appears on the cell surface of a wide range of cancers including Lung, Breast, Colorectal, and Prostate, but is absent in healthy tissue. Drugs targeting nfP2X7 have the potential to treat a wide variety of cancers, with minimal side effects, and in doing so win a significant place in the forecast US\$41 billion p.a. market.

Biosceptre have utilised this marker and have developed multiple biological therapies that unmask the cancer to the body's own immune system and stimulates the patient's own immune system to target the cancers. This bio-marker appears on the cancer cells only.

The advantage of this technology is that activates the body's own immune system against the cancer cells. The company has shown that the marker has been identified on the surface of cancerous cells in 18 to the top 20 cancers.

Stimulating a patient's own immune system to fight cancers provides a therapeutic approach to treat cancers that are treated poorly by existing therapeutics. Biosceptre BIL06v vaccine has demonstrated signs of efficacy in a number of Special Access Patients.

These funds are to be utilised to progress the company's:

- 3 clinical trials in the USA for the Vaccine BIL06v, Antibody BIL03s and Antibody BIL04s
- Undertake a China based clinical trial
- Progress marketing approval applications with the FDA in the USA, the National Medical Products Administration (NMPA) in China and other registrations for the rest of world on the back of successfully completed registrational clinical trials

Biosceptre has a very solid Intellectual Property position holding well over 100 patents across fourteen patent families surrounding nfP2X<sub>7</sub>

Another opportunity is accessing the Chinese domestic market, the company is also seeking a suitably qualified Joint Venture party with whom they can work with to undertake Chinese domestic clinical trials and then distribution throughout China. The company is most willing to open a research, development and commercial operations office in China, with the goal of eventually listing this business on a suitable Asian stock exchange. One of the existing shareholders, Tsinghua Science park (TusPark) who owns about 5% of Biosceptre are very interested in participating in the development of the domestic Chinese Joint Venture.

The company comprises; very experienced Executive Management/Board directors, and a Clinical Advisory Board comprising World Key Opinion makers, including the Chairman who is the 2018 Nobel Prize Winner in Chemistry.

Significant potential exits for the company to utilise its technology through acquiring a FDA Rare Pediatric Priority Review Voucher – market Value 2015-2017 USD\$125-\$350 million with supporting trials offered through two investigator initiated trials at Universitätsklinikum Tübingen - Children's Hospital and National Cancer Centre Singapore (no cost to the company).

Competitive Advantages - No current cancer therapeutics have achieved the potential breadth of efficacy attributed to this immune system response solution

Exit Strategy – IPO planned for 18 months, there is considerable upside from investing in this company before the IPO is completed.

**We welcome your interest in this project; for further information and discussions please contact Peter Beaumont at [Peter.Beaumont@litmusequity.com](mailto:Peter.Beaumont@litmusequity.com) or Elizabeth Gu at Litmus Equity on [Elizabeth.Gu@litmusequity.com](mailto:Elizabeth.Gu@litmusequity.com).**

Disclaimer: This document is issued by Litmus Equity and has been prepared from information from varying sources deemed to be reliable but it cannot be guaranteed as completely accurate and should not be relied upon as such. No warranties or guarantees are implied or offered. Independent Due Diligence by the investor or related parties is entirely the responsibility of the recipient. This document does not constitute personal advice and investors should obtain professional advice as to whether this investment suits their objectives, financial situation or needs. Investors should read and carefully consider the Information Memorandum before investing and speak to their financial planner. The performance figures shown in this report are derived from assumptions, data and materials collated. This document may be withdrawn, updated or replaced without notice.